Biocept, Inc.
BIOCQ · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $25,858 | $61,249 | $27,461 | $5,529 |
| % Growth | -57.8% | 123% | 396.7% | – |
| Cost of Goods Sold | $28,440 | $37,764 | $21,337 | $10,978 |
| Gross Profit | -$2,582 | $23,485 | $6,124 | -$5,449 |
| % Margin | -10% | 38.3% | 22.3% | -98.6% |
| R&D Expenses | $6,161 | $4,960 | $5,220 | $4,697 |
| G&A Expenses | $16,113 | $12,614 | $9,973 | $6,970 |
| SG&A Expenses | $23,240 | $20,934 | $16,373 | $12,911 |
| Sales & Mktg Exp. | $7,127 | $8,320 | $6,400 | $5,941 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $29,401 | $25,894 | $21,593 | $17,608 |
| Operating Income | -$31,983 | -$2,409 | -$15,469 | -$23,057 |
| % Margin | -123.7% | -3.9% | -56.3% | -417.1% |
| Other Income/Exp. Net | -$229 | -$290 | -$2,338 | -$2,081 |
| Pre-Tax Income | -$32,212 | -$2,699 | -$17,807 | -$25,138 |
| Tax Expense | -$125 | $125 | $0 | $0 |
| Net Income | -$32,087 | -$2,824 | -$17,807 | -$25,138 |
| % Margin | -124.1% | -4.6% | -64.8% | -454.7% |
| EPS | -56.78 | -5.73 | -45.1 | -365.01 |
| % Growth | -890.9% | 87.3% | 87.6% | – |
| EPS Diluted | -56.78 | -5.73 | -45.1 | -365.01 |
| Weighted Avg Shares Out | 565 | 493 | 395 | 69 |
| Weighted Avg Shares Out Dil | 565 | 493 | 395 | 69 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $316 | $290 | $236 | $250 |
| Depreciation & Amortization | $1,655 | $1,530 | $1,001 | $773 |
| EBITDA | -$30,241 | -$879 | -$16,569 | -$24,115 |
| % Margin | -117% | -1.4% | -60.3% | -436.2% |